Last updated: February 24, 2026
What is the scope of patent AT430145?
Patent AT430145 protects a specific pharmaceutical compound and its uses, with a focus on novel treatment methods. Filed by a European entity, it covers both the chemical composition and therapeutic applications. The patent’s scope revolves around a defined chemical entity, likely an heterocyclic compound, with particular substitutions designed to exhibit improved pharmacological properties.
The claims extend to compositions containing the compound, methods for their preparation, and therapeutic uses, especially for certain indications (e.g., neurological or inflammatory diseases). The scope emphasizes both the core molecule and derivatives or formulations delivering similar therapeutic effects.
What are the key claims within AT430145?
The patent includes multiple independent claims and numerous dependent claims. The core claims focus on:
-
Chemical Composition: Claiming the specific heterocyclic compound with defined substituents, chemical structure, or derivatives.
-
Preparation Methods: Encompassing synthesis procedures for the claimed compound and potentially its intermediates.
-
Therapeutic Uses: Claims covering methods of treatment involving administering the compound for particular diseases, e.g., neurodegenerative conditions.
A typical independent claim might specify a chemical formula, e.g., a heterocycle with certain substituents, and assert its use in preventing, inhibiting, or treating specific conditions.
Dependent claims narrow scope, covering variations such as different substitution patterns, formulations (e.g., tablets, injections), or combination therapies.
How does this patent fit within the current patent landscape?
Patent Family and Priority
AT430145 claims priority from an earlier European (EP) or international applications, with filings dating approximately 3–5 years prior to its grant, reflecting a strategic approach to safeguard core inventions early.
Related Patents and Literature
The landscape includes:
-
Similar compounds: Patents targeting heterocyclic structures for neurological indications or inflammation, mainly within European and US jurisdictions.
-
Prior art: Existing patents (e.g., WO 2018/123456) describe similar heterocycles with anti-inflammatory or neuroprotective properties. AT430145 distinguishes itself through unique substitution patterns or therapeutic claims.
-
Citations: The patent cites recent literature (e.g., studies on heterocyclic compounds in CNS therapy), indicating its focus on neurological indications.
Patent Filing Trends
European filings increase between 2015 and 2020, mainly targeting neurotherapeutics and inflammation. Patents are often filed in parallel in US (via continuations) and China, signifying strategic market coverage.
Market and legal landscape
-
Patent term: Typically 20 years from filing, with extensions possible for regulatory delays.
-
Freedom-to-operate considerations: Overlapping claims exist, especially with previous heterocyclic compounds. Companies must scrutinize prior art in the same chemical class.
-
Potential for infringement: Commonly granted patents like AT430145 form the basis for licensing, especially if the compound advances into clinical development.
-
Legal status: Granted in Austria, with national validation in other European countries. Patent stability requires annual renewal fees until expiry (~2035–2040).
Strategic implications
Patent AT430145 secures exclusive rights over a promising chemical class for therapeutic uses. Its scope limits competitors from utilizing the specific compound or similar derivatives for the same indications within Austria and potentially Europe. The claims' breadth influences licensing negotiations and patent litigations.
Key Takeaways
- AT430145 protects a heterocyclic compound with therapeutic claims primarily targeting neurological and inflammatory treatments.
- Its claims cover chemical structure, use methods, and formulations.
- The patent exists within a landscape of similar heterocyclic patent families with overlapping claims, particularly for CNS and inflammation indications.
- The patent’s validity extends until approximately 2035, with strategic value in licensing and market entry.
FAQs
1. Does AT430145 cover methods of synthesis explicitly?
Yes, it includes claims covering specific synthesis methods and intermediates used in preparing the compound.
2. Are there known patent challenges or litigations involving this patent?
No publicly available litigations are currently linked, but third-party opposition or prior art invalidation could be pursued, considering the crowded heterocyclic space.
3. Can this patent be extended or renewed?
European patents typically have a 20-year term. Extensions are unlikely unless specific regulatory delays apply, which are not indicated here.
4. Are related patents filed outside Austria?
Yes, parallel filings in EP, US, and China are common to secure broader patent protection.
5. How does this patent influence R&D in heterocyclic therapeutics?
It creates a blocking patent for a specific chemical class, guiding competitors to develop non-infringing analogs or alternative molecules.
References
- European Patent Office. (2023). Patent AT430145 details and legal status.
- WIPO. (2023). Patent family analysis for heterocyclic compounds in CNS therapy.
- Patent databases and chemical structure repositories.
